Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing
2024年4月11日 - 9:00PM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the
publication of a study from Penn State College of Medicine that
used optical genome mapping (OGM) to search for clinically and
biologically relevant genomic variations in pediatric B-cell acute
lymphoblastic leukemia (B-ALL). The study also used whole genome
sequencing (WGS) for variant detection and evaluated the two
approaches side-by-side and the potential benefit of
integrating WGS and OGM to obtain a comprehensive analysis of
genetic variation. The study concluded that OGM together with WGS
can potentially identify new therapeutic targets and improve
personalized medicine in pediatric leukemia and other cancers by
providing a more complete view of genome variation, including
structural variation.
The study findings showed that, of the 3,075 total SVs
detected in the B-ALL samples, 1,255 were uniquely detected by OGM.
The study also found that WGS detected 66 gene fusions, and that
OGM was able to detect an additional 56 fusions that were missed by
WGS. Several of the gene fusions detected by OGM were also not
previously found by other methods of analysis, and their expression
was confirmed by RNA sequencing, indicating their potential to be
used as prognostic biomarkers or possible therapeutic targets.
These study findings highlight the potential benefit of using OGM
for SV detection in B-ALL, as many SVs went undetected with WGS
alone.
Erik Holmlin, PhD, president and chief executive officer of
Bionano, commented, “We believe OGM’s ability to interrogate
genome-wide SVs in an important size range makes OGM a viable
alternative to traditional cytogenetic methods, and potentially a
strong complement to sequencing. These study results highlight the
potential benefit of adding OGM to a WGS workflow for a more
comprehensive analysis of genetic variation in blood cancers, which
may improve clinical diagnostics in future research, as better
resolution of SVs can help illuminate the genetic drivers in
cancer.”
The publication is available
at: https://www.mdpi.com/2075-4426/14/3/291
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
The Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. The Company additionally offers
nucleic acid extraction and purification solutions using
proprietary isotachophoresis (ITP) technology. For more
information,
visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Bionano’s OGM products are for research use only and not for use
in diagnostic procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “can,” “may,” “potential” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) convey
uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: the ability and utility of OGM to detect SVs
and gene fusions in pediatric B-ALL samples; the utility of OGM to
identify new therapeutic targets and improve personalized medicine
in pediatric leukemia and other cancers; the utility of combining
OGM with WGS to identify new therapeutic targets and improve
personalized medicine in pediatric leukemia and other cancers; the
utility of adding OGM to a WGS workflow for a more comprehensive
analysis of genetic variation in blood cancers and improve clinical
diagnostics in future research; and other statements that are not
historical facts. Each of these forward-looking statements involves
risks and uncertainties. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: the impact of geopolitical
and macroeconomic developments, such as recent and potential future
bank failures, supply chain disruptions, global pandemics,
inflation and the ongoing conflicts between Ukraine and Russian and
Israel and Hamas, on our business and the global economy; general
market conditions; the failure of OGM to detect SVs and gene
fusions in pediatric B-ALL samples; the failure of OGM to identify
new therapeutic targets and improve personalized medicine in
pediatric leukemia and other cancers; the failure of combining OGM
with WGS to identify new therapeutic targets and improve
personalized medicine in pediatric leukemia and other cancers; the
failure of adding OGM to a WGS workflow for a more comprehensive
analysis of genetic variation in blood cancers and improve clinical
diagnostics in future research; study results that differ or
contradict the results reported in the study referenced in this
press release; changes in the competitive landscape and the
introduction of competitive technologies or improvements to
existing technologies; changes in our strategic and commercial
plans; our need and ability to obtain sufficient financing to fund
our strategic plans and commercialization efforts, our ability to
effectively manage our uses of cash, and our ability to continue as
a “going concern”; the ability of medical and research institutions
to obtain funding to support adoption or continued use of our
technologies; and the risks and uncertainties associated with our
business and financial condition in general, including the risks
and uncertainties described in our filings with the Securities and
Exchange Commission, including, without limitation, our Annual
Report on Form 10-K for the year ended December 31, 2023 and in
other filings subsequently made by us with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
過去 株価チャート
から 4 2024 まで 5 2024
Bionano Genomics (NASDAQ:BNGO)
過去 株価チャート
から 5 2023 まで 5 2024